• Project ALS Granted FDA Orphan Drug Designation for Prosetin americanpharmaceuticalreview
    September 17, 2020
    Project ALS announced the Food and Drug Administration (FDA) has granted orphan drug designation to prosetin for the treatment of ALS. Prosetin is an oral, brain penetrant MAP4 kinase inhibitor developed by scientists at Columbia University for the ...
PharmaSources Customer Service